Sarepta Therapeutics Receives Average Rating of “Buy” from Brokerages (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT) has received an average recommendation of “Buy” from the twenty-one ratings firms that are presently covering the company, American Banking & Market News reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $40.00.
Several analysts have recently commented on the stock. Analysts at Cowen and Company initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, August 19th. They set an “outperform” rating and a $44.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Sarepta Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $45.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “positive” rating on shares of Sarepta Therapeutics in a research note on Wednesday, July 30th.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 23.20 on Wednesday. Sarepta Therapeutics has a 1-year low of $12.12 and a 1-year high of $55.61. The stock’s 50-day moving average is $21.90 and its 200-day moving average is $27.90. The company’s market cap is $949.4 million.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.85) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.76) by $0.09. The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $4.30 million. During the same quarter last year, the company posted ($0.46) earnings per share. Sarepta Therapeutics’s revenue was down 12.5% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post $-3.58 EPS for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.